Skip to main content

TransMedics Group, Inc.

For the period ended Sep 30, 2025. Filed Oct 29, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Oct 29, 2025

TMDX$90.95-3.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations

(In thousands, except share and per share amounts)

Three Months Ended September 30,Nine Months Ended September 30,
2025202420252024
Revenue:
Net product revenue$87,677$65,861$272,011$198,918
Service revenue56,14642,900172,719120,998
Total revenue143,823108,761444,730319,916
Cost of revenue:
Cost of net product revenue18,68713,24654,42041,800
Cost of service revenue40,56134,670120,91888,048
Total cost of revenue59,24847,916175,338129,848
Gross profit84,57560,845269,392190,068
Operating expenses:
Research, development and clinical trials15,26014,26648,35439,504
Selling, general and administrative46,01542,656133,728121,712
Total operating expenses61,27556,922182,082161,216
Income from operations23,3003,92387,31028,852
Other income (expense):
Interest expense(3,491)(3,617)(10,428)(10,838)
Interest income and other income (expense), net3,2223,9399,00710,777
Total other income (expense), net(269)322(1,421)(61)
Income before income taxes23,0314,24585,88928,791
(Provision) benefit for income taxes1,288(29)(981)(184)
Net income$24,319$4,216$84,908$28,607
Net income per share:
Basic$0.71$0.13$2.50$0.86
Diluted$0.66$0.12$2.28$0.81
Weighted average common shares outstanding:
Basic34,112,45233,441,39433,917,00633,108,253
Diluted40,748,02335,683,95240,410,20835,218,756
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.